key: cord-0734304-9viof979 authors: Pandrowala, Saneya; Ramraj, Deepak; Shankar, Ravi; Chopra, Saumya; Das, Abhishek; Mishra, Aseem; Pandey, Durgatosh title: Impact of preoperative COVID infection on the outcomes of planned curative‐intent cancer surgeries in the second wave of the pandemic from a tertiary care center in India date: 2021-09-27 journal: J Surg Oncol DOI: 10.1002/jso.26697 sha: 35f9da3340f4aa52bb38b816065fa46350e20959 doc_id: 734304 cord_uid: 9viof979 BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic was an unforeseen calamity. Sudden disruption of nonemergency services led to disruption of treatment across all specialties. Oncology revolves around the tenet of timely detection and treatment. Disruption of any sort will jeopardize cure rates. The time interval between coronavirus infection and cancer surgery is variable and needs to be tailored to avoid the progression of the disease. METHODS: We analyzed the impact of preoperative coronavirus disease 2019 (COVID‐19) infection on the planned cancer surgery, delay, disease progression, and change of intent of treatment from April 1 to May 31, 2021 at a tertiary care center. All preoperative positive patients were retested after 2 weeks and were considered for surgery if the repeat test was negative and asymptomatic. FINDINGS: Our study included 432 preoperative patients of which 91 (21%) were COVID‐19 positive. Amongst this cohort, 76% were operated and the morbidity and mortality were comparable to the COVID‐19 negative cohort. Around 10% of the COVID‐19 positive were lost to follow up and 10% had disease progression and were deemed palliative INTERPRETATION: SARS‐CoV‐2 infection has adversely impacted cancer care and a 2‐week waiting period postinfection seems to be a safe interval in asymptomatic individuals to consider radical cancer surgery. detection, diagnosis, and treatment completion. Delay of any sort will lead to stage migration and jeopardize cure rates. Experience gained from the first wave suggests that with suitable guidelines major cancer surgeries can be performed without increase morbidity or mortality. 3 4 This has possibly led to inordinate delay from decision making to the actual execution of surgery. This leads to a long treatment gap and possible disease progression. We followed a protocol of repeating an RT-PCR two weeks after a positive report and considering patients for surgery with a negative report. In this article, we have analyzed short-term outcomes for patients who were detected to be coronavirus disease 2019 (COVID-19)-positive during initial preoperative testing and had delayed surgery after testing negative and compared them with COVID-19-negative patients operated during the same timeframe. We have also assessed the impact of delay due to preoperative COVID-19 infection on disease progression and intent of treatment. We conducted a retrospective analysis of a prospectively maintained database of April and May 2021 that was the peak of the second wave with massive numbers of daily positive reports in the state of Uttar Pradesh. We restricted our analysis to those cancer patients who were planned for surgery with curative intent. Our policy, in general, was to repeat a COVID-19 RT-PCR test after 2 weeks of a positive report and consider surgery if the patient was asymptomatic and had turned negative on repeat RT-PCR. Patients with a negative RT-PCR were admitted within 72 h of the report, most patients being admitted within 24 h. All patients in the initial preoperative positive group were assessed by a complete cardiopulmonary workup including chest X-ray or computed tomography thorax, two-dimensional echocardiography, and a 6min walk test. If deemed unfit they were optimized and then operated. We analyzed the number of patients in whom the intent of treatment changed from curative to palliative due to the delay in treatment, patients lost to follow-up, and operative morbidity of such patients as infection was taken as the postoperative day it was detected. Morbidity was measured using the Clavein-Dindo scoring. The study was approved by the Institutional Ethics Committee. The data was recorded in the prospective database of the disease management groups, and complete records for delay in surgery were added using Statistical Product and Service Solutions (SPSS), IBM Corp, for Windows version 21.0, (SPSS Inc.). Descriptive analyses were performed for age, sex, surgery performed, and delay due to COVID-19, while intraoperative and postoperative parameters were compared between patients with and without preoperative infection. There were a total of 432 preoperative patients who underwent RT-PCR testing in the defined study period ( Table 1 . Most patients (89%) had an asymptomatic COVID-19 infection and were detected on routine preoperative testing. While comparing operated cases between the COVID-19-positive cohort and those who were always COVID-19-negative, the age group was similar (47.3 vs. 47.7 years), there was a preponderance of male sex, oral cavity, and breast primary in both groups, the duration of hospital stay (7.8 vs. 6 days) as well as the in-hospital morbidity (12.9% vs. 12.7%) were comparable between the two groups. The 30-day mortality was 2.5% in the COVID-19-positive group, while it was 0.6% in the COVID-19negative group. The median delay in surgery in those 67 patients who were tested COVID-19-positive in their initial preoperative RT-PCR but could undergo surgery later was 23 days (7-60). have been delays from referrals to diagnoses to definitive treatment including surgeries which has resulted in the loss of lives. [12] [13] [14] [15] [16] The paramount fact to be gathered is that unless we continue cancer care as routine, we will be losing lives over and above the lives lost due to the pandemic. To the best of our knowledge, the impact of delays due to preoperative COVID-19 infection and follow-up of these patients has not been published. Post novel coronavirus infection, recent COVID-19Surg Collaborative international prospective study has defined more than or equal to 7 weeks intervals for surgery to reduce perioperative mortality to baseline. 17 However, National Cancer Database has calculated a safe postponement period for cancer surgeries to be 4 weeks without adversely affecting survival or disease progression. 18 This implies that we need a middle ground for cancer surgeries accepting the possible slightly increased morbidity to balance disease progression. We also need to be cognizant of the fact that different cancers have different biological clocks, and the extrapolation of data will be erroneous. Delays during the pandemic have resulted in an increase in neoadjuvant chemotherapy for pancreatic cancer and colorectal liver metastases and locoregional treatment for hepatocellular carcinoma. 19 During the peak second wave of the pandemic, our data shows that approximately 10% of patients were rendered palliative even though our services were fully functioning without any reduction in capacity. An integral part of disaster management is preparedness to mitigate another hit. Unfortunately, India has been one of the worst-hit nations in the second wave of the pandemic. To get ahead of the pandemic we need to create virus-free zones and declare cancer care as a priority rather than wait for the surge to decline. 23 , 24 We also need a better and comprehensive guideline for infected and recovered patients to guide treatment decisions that are time sensitive. SARS-CoV-2 infection has adversely impacted cancer care and a 2-week waiting period post-SARS-CoV-2 infection seems to be a safe interval in asymptomatic individuals to consider radical cancer surgery. This will ensure the safe and timely delivery of curative-intent treatment. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Durgatosh Pandey http://orcid.org/0000-0002-3043-4892 Impact of COVID-19 on cancer care in India: a cohort study COVID-19 variants in India: potential role in second wave and impact on vaccination Outcomes of elective major cancer surgery during COVID 19 at Tata Memorial Centre: implications for cancer care policy Postoperative mortality among surgical patients with COVID-19: a systematic review and metaanalysis Cancer management in India during COVID-19 Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal Discordance of COVID-19 guidelines for patients with cancer: a systematic review Continuing surgical care in cancer patients during the nationwide lockdown in the COVID-19 pandemic-Perioperative outcomes from a tertiary care cancer center in India Maintaining surgical treatment of non-small cell lung cancer during the COVID-19 pandemic in Paris Is elective cancer surgery safe during the COVID-19 pandemic? Outcomes of elective head and neck confirmed or suspected cancer surgery during the COVID-19 pandemic Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans How many lives will delay of colon cancer surgery cost during the COVID-19 pandemic? An analysis based on the US National Cancer Database The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study DElayed COloRectal cancer care during COVID-19 Pandemic (DECOR-19): global perspective from an international survey Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study Are we harming cancer patients by delaying their cancer surgery during the COVID-19 pandemic? Ann Surg Delivery of hepatopancreato-biliary surgery during the COVID-19 pandemic: an European-African Hepato-Pancreato-Biliary Association (E-AHPBA) cross-sectional survey Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study Analysis of worldwide surgical outcomes in COVID-19-infected patients: a gynecological oncology perspective The day after tomorrow: how should we address health system organization to treat cancer patients after the peak of the COVID-19 epidemic? Surgical oncologists and the COVID-19 pandemic: guiding cancer patients effectively through turbulence and change Impact of preoperative COVID infection on the outcomes of planned curative-intent cancer surgeries in the second wave of the pandemic from a tertiary care center in India